15396-41-5 Usage
Uses
Used in Medical Imaging:
2,3,5-triiodo-benzoic acid methyl ester is used as a contrast agent for enhancing the visibility and contrast of certain tissues and organs in imaging techniques such as X-ray, CT scans, and MRI. The presence of three iodine atoms in its structure allows for better differentiation and assessment of internal body structures during diagnostic procedures.
Used in Pharmaceutical Production:
2,3,5-triiodo-benzoic acid methyl ester is utilized as a chemical intermediate in the synthesis of various pharmaceutical compounds. Its role in drug development is crucial, as it contributes to the creation of new medications that can address a range of health conditions.
Used in Diagnostic Reagents:
2,3,5-triiodo-benzoic acid methyl ester is also employed in the production of diagnostic reagents, which are essential tools in medical diagnostics. The reagents help in identifying and measuring various substances in biological samples, thereby aiding in the accurate diagnosis of diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 15396-41-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,3,9 and 6 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 15396-41:
(7*1)+(6*5)+(5*3)+(4*9)+(3*6)+(2*4)+(1*1)=115
115 % 10 = 5
So 15396-41-5 is a valid CAS Registry Number.
15396-41-5Relevant academic research and scientific papers
Delivery of x-ray contrast agents using receptor mediated endocytosis
-
, (2008/06/13)
The invention provides a method of targeting an x-ray contrast agent to a specific population of cells or organ. Targeting may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the target cells or organ by visualizing the extent, mode of uptake and excretion of the targeted x-ray contrast agent by x-ray or computer tomography.
